Rigel Pharmaceuticals, Inc. (RIGL)

NMS – Цена в реальном времени. Валюта: USD

38.69

+1.70 (4.60%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

38.40

-0.29 (-0.75%)

После закрытия: Jun 26, 2026, 7:18 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Rigel Pharmaceuticals, Inc. (RIGL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)

Rigel to Present at the Jefferies Global Healthcare Conference

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference

Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

Видео

No Data

Пресс-релизы

Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

Rigel Reports First Quarter 2026 Financial Results

Search stocks

Rigel Pharmaceuticals, Inc. (RIGL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)

Rigel to Present at the Jefferies Global Healthcare Conference

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference

Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

Видео

No Data

Пресс-релизы

Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

Rigel Reports First Quarter 2026 Financial Results